UBS has initiated coverage on RxSight Inc. (NASDAQ: RXST) with a Buy rating and a price target of $52, citing strong growth potential in the U.S. cataract surgery market, particularly for its Light Adjustable Lens (LAL) technology. The company is projected to achieve over 20% sales growth through 2028, with a current ratio of 12.67 and minimal debt, positioning it for continued expansion. In Q3 2024, RxSight reported a 59% revenue increase to $35.3 million, driven by LAL sales, and plans to deepen market penetration in North America while expanding globally in 2025.